Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 6 records per page: next > | last >>
pages: 1 2 3 4 5 6 presentations: 1 to 25 of 131
From discovery to clinics: Design considerations in biomarker studies
Yingye Zheng
Fred Hutchinson Cancer Research Ctr., Seattle, WA, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Needle in a haystack: Biomarker discovery in high-dimensional data
Shilin Zhao
Vanderbilt University Medical Center, Nashville, TN, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Precision oncology: Integrating biomarkers in phase III clinical trial designs
Antje Hoering
Cancer Research and Biostatistics, Seattle, WA, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Population risk stratification: Integrating biomarkers in cancer risk assessment
Ruth Pfeiffer
NCI-DCEG, Bethesda, MD, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Discovery of BLU-667 for RET driven cancers
Jason Brubaker
Blueprint Medicines, Cambridge, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Discovery and development of USP7 inhibitors
Tim Harrison
Almac Discovery, Belfast, Ireland
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Identification and optimization of chemical series that lead to discovery of erdafitinib: A potent pan-fibroblast growth factor receptor (FGFR) inhibitor
Patrick Angibaud
Janssen R & D, Val-de-Reuil, France
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Development of potent and selective CD73 inhibitors: Discovery and characterization of AB680
Jenna Jeffrey
Arcus Biosciences, Inc., Hayward, CA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
How to develop trial objectives: Translation of science from bench to bedside to bench
Patricia M LoRusso
Yale Cancer Center, New Haven, CT, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Modernizing eligibility criteria for oncology clinical trials
Tatiana Prowell
U.S. Food and Drug Administration and Johns Hopkins Kimmel Cancer Center, Silver Spring, MD, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Biostatistical principals of clinical trial design
Mithat Gonen
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Designing meaningful and impactful clinical trials
Jyoti D Patel
Univ. of Chicago Medical Ctr., Chicago, IL, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
The changing landscape of oncology drug development
David S Hong
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
GO/NO GO decisions in cancer drug discovery: Has the decision making process evolved?
Nancy E. Kohl
Consultant, Wellesley, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Insights from a clinical development prediction algorithm: What we measure matters
David Feltquate
Bristol-Myers Squibb, New York, NY, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Pivotal decision making in oncology drug development: A perspective
Sandra J. Horning
Genentech, Inc., San Francisco, CA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Is there a place for traditional phase 2 trials in cancer drug development?
Michael A. Carducci
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
The promises and challenges of master protocols: Basket and umbrella trials and beyond
Marc Theoret
U.S. Food and Drug Administration, Silver Spring, MD, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Meaningful biostatistical outcomes of expansion cohort trials
Alexia Iasonos
Memorial Sloan Kettering Cancer Center, New Y ork, NY, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
The multi-trial platform design: When and how?
Lorenzo Trippa
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Improving nerve tissue preservation using fluorescence guided surgery for improved clinical outcomes
Summer L Gibbs
Oregon Health & Science University, Portland, OR, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Microdose clinical trials update with fluorescent anti-EGFR Affibody ABY-029
Brian W Pogue
Dartmouth College, Hanover, NH, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Optical and optoacoustic imaging: a hyperloop mechanism for drug development and optical tracer evaluation
Gooitzen M van Dam
University Medical Center Groningen, Groningen, Netherlands
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Optical surgical navigation using fluorescently labeled antibodies during head and neck cancer resection
Jason M. Warram
University of Alabama at Birmingham, Birmingham, AL, United States
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
Introduction
Richard M. Marais
Cancer Research UK Manchester Inst., Manchester, United Kingdom
from AACR Annual Meeting 2019 on March 30, 2019 10:15 AM-12:15 PM
<< first | < prev page: of 6 records per page: next > | last >>
pages: 1 2 3 4 5 6 presentations: 1 to 25 of 131